ZyVersa Therapeutics, Inc.

NasdaqCM ZVSA

ZyVersa Therapeutics, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2024

ZyVersa Therapeutics, Inc. Free Cash Flow Per Share is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Free cash flow per share is the free cash flow generated per share. Indicates investment potential based on cash flow generation.

ZyVersa Therapeutics, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -132.59, a -229.25% change year over year.
ZyVersa Therapeutics, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -40.27.

Key data

Date	Free Cash Flow Per Share	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)

NasdaqCM: ZVSA

ZyVersa Therapeutics, Inc.

CEO	Mr. Stephen C. Glover
IPO Date	Feb. 11, 2022
Location	United States
Headquarters	2200 N. Commerce Parkway
Employees	7
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

Key trends

Past 5 years